Malawi’s health sector is grappling with a serious lack of trained health care staff that could have an impact on its Global Fund-supported programming to enroll a greater number of HIV-positive Malawians on antiretroviral therapy (ART).
The Global Fund Secretariat is working with 20 countries in sub-Saharan Africa to assess the possibility of reprogramming existing Global Fund grants to allow for a switch from the use of single dose nevirapine to more effective dual or triple ARV therapy for the prevention of mother-to-child transmission (PMTCT).
In Issue 111, GFO reported briefly on a Global Fund Board decision in November 2009 to further modify its Quality Assurance Policy for Pharmaceutical Products. This article provides some background information and further details of the decision.
The Board had previously approved a revised Quality Assurance Policy at its meeting in November 2008. That revised policy came into effect on 1 July 2009.
The Global Fund announced this month that a cumulative total of 1.75 million people living with HIV have been reached with antiretroviral (ARV) treatment through AIDS programs it supports, a 59 per cent increase over the totals as of a year ago.
Something quite remarkable happened a few days ago. On Thursday 25 September, a simple and obvious proposal was made by Stephen Lewis, the passionate Canadian who serves as the UN Secretary-General's Special Envoy for HIV/AIDS in Africa. Speaking at a conference on AIDS in Nairobi, he said that Canada should issue a compulsory license to lift the patent protection that covers most anti-retroviral drugs (ARVs).